PAVM:NASDAQPAVmed Inc. analysis

Technical outlook: PAVmed trades at $5.36, barely above its 52‑week low of $3.85 and just above the 20‑day SMA (5.13) while remaining under the 50‑day (6.55) and 200‑day (9.60) averages, signaling a bearish longer‑term trend. The RSI sits at 47.6 (neutral) and the MACD histogram is positive (0.11) despite both lines being negative, suggesting a modest short‑term bullish tilt, reinforced by an increasing volume trend. However, the stock exhibits extreme short‑term volatility (≈78% 30‑day) and a high beta of 1.65, indicating strong sensitivity to market swings.
Fundamental outlook: The company’s financial health is fragile: revenue is only $85 k with 1.75% growth, gross margin is –2.3% and operating margin plunges to –365%, leading to a –$24.3 M EBITDA and negative free cash flow. Cash ($6.8 M) is far below total debt ($17 M) with a debt‑to‑equity ratio of 68%, and there is no dividend. While valuation metrics show an eye‑popping upside potential of ~572% and a price‑to‑book of 0.94, the massive losses, cash burn, and high leverage outweigh any speculative upside.